Transforming Pharma: The GLP-1 Gold Rush

This report by Allianz Research examines the transformative impact of GLP-1 weight-loss drugs on the pharmaceutical industry, public finances, and the insurance sector. It outlines the significant growth in sales of GLP-1 medications, which have surged from EUR4.5 billion in 2021 to EUR21.2 billion in 2023, driven by products like Semaglutide and Tirzepatide. The report details the potential for these drugs to reshape the market, with predictions of revenues reaching EUR92 billion by 2030. However, it also highlights risks such as regulatory scrutiny and the emergence of generic alternatives. The report discusses the implications for health expenditures, estimating potential savings of EUR3.3 trillion globally due to reduced obesity rates. Furthermore, it addresses the effects on the food industry, which may need to adapt to changing consumer behaviors. The insurance sector is also expected to benefit from lower claims as obesity rates decline. Overall, the report presents a comprehensive view of the GLP-1 market dynamics and their broader economic implications.